Pfizer Inc. 2025 Annual Report (Form 10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for Pfizer Inc. for the fiscal year ended December 31, 2025. Pfizer is a research-based, global biopharmaceutical company. The company operates through three segments: Biopharma (the only reportable segment), Pfizer CentreOne (PC1), and Pfizer Ignite (which was discontinued in 2025). Key strategic priorities for 2026 include maximizing the value of key transactions (specifically the Metsera and Seagen acquisitions), delivering on R&D milestones, investing for post-2028 growth, and scaling AI across the business.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $62.6 billion | $63.6 billion | -2% (Reported) |
| Net Income (GAAP) | $7.8 billion | $8.0 billion | -3% |
| Diluted EPS (GAAP) | $1.36 | $1.41 | -3% |
| Adjusted Diluted EPS (Non-GAAP) | $3.22 | $3.11 | +4% |
| Operating Cash Flow | $11.7 billion | $12.7 billion | -8% |
| Cost of Sales | $16.1 billion | $17.9 billion | -10% |
| R&D Expenses | $10.4 billion | $10.8 billion | -4% |
| Acquired IPR&D Expenses | $1.6 billion | $0.1 billion | Significant Increase |
| Total Debt (Long-term + Current) | $64.8 billion | $64.4 billion | Flat |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 2% operationally, primarily driven by significant declines in COVID-19 product revenues (Comirnaty down 20% operationally; Paxlovid down 59% operationally). Excluding Comirnaty and Paxlovid, total revenues increased 6% operationally.
- Product Growth: Growth was driven by the Vyndaqel family (+16%), Eliquis (+7%), Padcev (+22%), Lorbrena (+40%), and Abrysvo (+36%).
- Acquired IPR&D: Expenses surged to $1.6 billion (from $108 million in 2024) due to a $1.35 billion charge for an in-licensing agreement with 3SBio and a $150 million charge for an agreement with YaoPharma.
- Asset Impairments: The company recorded $4.9 billion in intangible asset impairments in 2025 (up from $3.3 billion in 2024), primarily related to changes in development plans and commercial forecasts for IPR&D assets.
- Acquisitions: Completed the acquisition of Metsera in November 2025 for approximately $8.0 billion to advance obesity and cardiometabolic therapies.
Guidance, Outlook, and Risks
Outlook and Guidance: Management expects the impact from patent-based or regulatory exclusivity expiries to be approximately $1.5 billion in 2026. The company anticipates a significant acceleration in revenue reduction from patent expiries between 2026 and 2030. The IRA Medicare Part D Redesign negatively impacted 2025 revenues by approximately $1 billion, with no material incremental impact expected in 2026 versus the 2025 baseline.
Key Risks and Contingencies:
- Patent Expirations: Significant revenue erosion is expected as key products face generic competition. Eliquis faces potential generic entry in 2028 (settled) or 2031 (litigation pending). Xeljanz faces patent expiry in 2026.
- Regulatory Environment: The Inflation Reduction Act (IRA) continues to impact pricing, with Eliquis subject to a government-set Maximum Fair Price effective January 1, 2026. Ibrance and Xtandi are selected for price negotiation effective 2027.
- Legal Proceedings: Ongoing litigation includes patent disputes (Comirnaty, Paxlovid, Eliquis), product liability suits (Zantac, Depo-Provera, Chantix), and government investigations.
- Product Withdrawals: Oxbryta was voluntarily withdrawn in 2024 due to safety concerns; the EMA adopted a negative opinion in October 2025.
- Trade and Tariffs: The company entered a voluntary agreement with the U.S. Government in September 2025 to lower drug prices in exchange for a three-year grace period on Section 232 tariffs, contingent on U.S. manufacturing investment.
Investor Verification Checklist
- COVID-19 Revenue Trajectory: Verify the sustainability of Comirnaty and Paxlovid revenue declines and the impact of seasonal demand on future quarters.
- Patent Cliff Exposure: Confirm the timeline and financial impact of upcoming patent expirations for Eliquis, Xeljanz, and Ibrance, including the status of ongoing litigation.
- Acquisition Integration: Assess the progress of integrating Metsera and Seagen, specifically regarding the realization of projected cost synergies and R&D milestones.
- IRA Impact: Monitor the actual financial impact of the Medicare Drug Price Negotiation Program (MDPNP) on Eliquis, Ibrance, and Xtandi starting in 2026 and 2027.
- Asset Impairments: Review the specific drivers of the $4.9 billion impairment charge to understand which pipeline assets were de-prioritized.
- Legal Reserves: Evaluate the adequacy of reserves for ongoing product liability litigation (e.g., Zantac, Depo-Provera) and patent disputes.